Critical Outcome T (OTCMKTS:COTQF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Cotinga Pharmaceuticals Inc. is a clinical-stage pharmaceutical company which uses proprietary artificial intelligence technologies to develop innovative therapies to treat a wide spectrum of cancers. The Company’s CHEMSAS(R) platform evaluates biological activity from molecular structures, allowing the Company to build a pipeline of potential drug candidates with predictive accuracy and expediency when compared to traditional development methods. Cotinga Pharmaceuticals Inc., formerly known as Critical Outcome Technologies Inc., is based in Boston, Massachusetts. “
Separately, ValuEngine raised Critical Outcome T from a “strong sell” rating to a “sell” rating in a research note on Friday.
Critical Outcome T (OTCMKTS:COTQF) last released its earnings results on Friday, December 29th. The company reported ($0.09) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.01.
Critical Outcome T Company Profile
Critical Outcome Technologies Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The companys proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Critical Outcome T Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome T and related companies with MarketBeat.com's FREE daily email newsletter.